HUTCHMED's 2025 Net Income Soars to $457M on Divestment Gain, ATTC Platform Advances

Big picture: profits up, revenue down, pipeline moving

HUTCHMED has posted a headline net income of $456.9 million for 2025, a sharp jump from $37.7 million in 2024. The lion’s share came from a $415.8 million net gain on the April divestment of a 45.0% stake in SHPL. Under the bonnet, total revenue fell 13% to $548.5 million as China oncology sales digested regulatory and commercial headwinds in the first half, before rebounding in the second.

Ex-China momentum continues for fruquintinib (FRUZAQLA®), while the new Antibody-Targeted Therapy Conjugate (ATTC) platform has moved from lab to clinic with two candidates now dosing patients. Cash at year end was a chunky $1,367.3 million, giving ample firepower for development and partnerships.

Key numbers you need to know

Metric	2025	2024	Comment
Total revenue	$548.5m	$630.2m	-13%, reflecting China oncology softness and 2024 one-off milestone
Oncology/Immunology revenue	$285.5m	$363.4m	-21%
In-market oncology sales (all brands)	$524.7m	$501.0m	+5%; H2 up 24% vs H1
FRUZAQLA® in-market (ex-China)	$366.2m	$290.6m	+26%; approvals in 38 countries to date
ELUNATE® in-market (China)	$100.1m	$115.0m	-13%; H2 up 33% vs H1
Net income attributable to HUTCHMED	$456.9m	$37.7m	Includes $415.8m net divestment gain
Cash, cash equivalents and short-term investments	$1,367.3m	$836.1m	Strengthened by SHPL proceeds
R&D expenses	$148.3m	$212.1m	Lower as late-stage trials completed
Basic EPS per ordinary share	$0.53	$0.04	ADS basic EPS $2.66

Commercial performance: FRUZAQLA leads, China rebounds in H2

FRUZAQLA® in-market sales by Takeda rose 26% to $366.2 million, buoyed by launches across Europe, Asia and the Americas, broader reimbursement and growing clinician familiarity in third-line-plus colorectal cancer. The team does flag some drag from the US Medicare Part D redesign, which affected many prescription medicines in 2025.

Inside China, the picture is mixed but improving. ELUNATE® delivered $100.1 million in-market (-13% year on year) yet grew strongly in the second half as HUTCHMED streamlined and refocused the salesforce. SULANDA® fell to $27.0 million (-45%) amid new entrants to China’s National Reimbursement Drug List, while ORPATHYS® was $28.9 million (-36%) in-market; AstraZeneca continues to push MET testing to steady demand. TAZVERIK® is small at $2.5 million but growing following its March 2025 approval.

Net: in-market oncology sales grew 5% overall, and the company points to a 24% sequential step-up in H2 as commercial changes bedded in. That inflection matters if 2026 is to show clean underlying growth, not just one-off gains.

ATTC platform: from promise to patients

ATTCs (Antibody-Targeted Therapy Conjugates) are HUTCHMED’s twist on antibody-drug conjugates: pairing a monoclonal antibody with a potent small-molecule inhibitor payload to deliver a one-two mechanism directly to tumour cells. The goal is higher efficacy with lower off-target toxicity.

• HMPL-A251 (PI3K/PIKK-HER2 ATTC) entered a global Phase I/IIa in December 2025 for HER2-expressing tumours after preclinical data showed robust anti-tumour activity and bystander effects.
• HMPL-A580 (PI3K/PIKK-EGFR ATTC) initiated a global trial in March 2026 for EGFR solid tumours; preclinical data to be presented at an upcoming conference.
• HMPL-A830 is targeting first-in-human by year end 2026.

Management is actively pursuing potential partnerships with multinationals in 2026. That is sensible: it de-risks development, can speed global trials and validates the platform, much like the FRUZAQLA® deal with Takeda.

Late-stage pipeline: multiple shots on goal

Savolitinib (ORPATHYS®)

• China approvals expanded in 2025 for MET-driven lung cancer, triggering an $11.0 million milestone from AstraZeneca. Swissmedic granted temporary authorization in February 2026 for use with TAGRISSO® in second-line EGFRm NSCLC with MET amplification/overexpression.
• Phase III SAFFRON (global, second-line EGFRm NSCLC with MET amp/overexp) has completed enrolment with topline data expected in H2 2026, which could support global filings.
• SANOVO (China, first-line EGFRm NSCLC with MET overexpression) readout due late 2026 or early 2027.

Fruquintinib (ELUNATE®/FRUZAQLA®)

• FRUSICA-2 Phase III in second-line kidney cancer (with TYVYT®) showed median progression-free survival (mPFS) of 22.2 months vs 6.9 months for axitinib/everolimus (HR 0.373; p<0.0001) and a 60.5% objective response rate.
• China sNDA for the combo in renal cell carcinoma was accepted in June 2025.

Sovleplenib (HMPL-523, Syk inhibitor)

• Warm autoimmune haemolytic anaemia (wAIHA): Phase III met primary endpoint; sNDA submission planned in H1 2026.
• Immune thrombocytopenia (ITP): NDA resubmitted in February 2026 after additional stability work to meet impurity limits; rolling data in H2 2026. HUTCHMED is seeking a partner for ex-China development.

Surufatinib (SULANDA®) and fanregratinib

• First-line metastatic pancreatic ductal adenocarcinoma (PDAC) combo delivered mPFS of 7.2 months vs 5.5 months; Phase III initiated in December 2025.
• Fanregratinib’s NDA for second-line intrahepatic cholangiocarcinoma (IHCC) with FGFR2 fusion/rearrangement was accepted with priority review in December 2025.

Cash runway and 2026 guidance

With $1.4 billion of cash and investments at year end, HUTCHMED has the resources to press on with ATTC trials and late-stage programmes. Operating discipline helped too: R&D fell to $148.3 million as costly pivotal studies wrapped up, and selling & administrative costs reduced to $103.0 million after streamlining the China commercial team.

For 2026, Oncology/Immunology consolidated revenue guidance is $330 million to $450 million. That range bakes in continued FRUZAQLA® expansion, a resumed growth trajectory in China, and potential ATTC partnering. It is a wide range, so execution and the timing of catalysts will be in focus.

Why this matters for investors

• Positive: Ex-China growth engine is working. FRUZAQLA® approvals in 38 countries and reimbursement in almost 20 underpin a multi-year ramp.
• Positive: China sales inflected in H2 2025 after commercial changes. If sustained, 2026 should look cleaner on a like-for-like basis.
• Positive: ATTC platform is now clinical with two assets. Early partnerships could add non-dilutive funding and external validation.
• Caution: 2025 profit was largely driven by the SHPL divestment. Core revenues fell 13%, and China remains competitive for SULANDA® and ORPATHYS®.
• Caution: US Medicare Part D redesign dented FRUZAQLA® in 2025. Pricing and reimbursement dynamics remain a live risk.

Near-term catalysts to watch

• SAFFRON Phase III topline (H2 2026) – potential path to broader savolitinib filings.
• Sovleplenib – wAIHA sNDA submission in H1 2026; ITP rolling data in H2 2026.
• Fanregratinib – priority review progress in FGFR2+ IHCC.
• Fruquintinib – China sNDA with sintilimab in renal cell carcinoma.
• ATTC – HMPL-A251 and HMPL-A580 early clinical updates; potential partnering announcements in 2026; HMPL-A830 first-in-human by year end.

My take

HUTCHMED delivered what the market likes to see: a fortified balance sheet, ex-China growth, and a credible new platform stepping into human studies. The flip side is that 2025’s profit was not from operations, and China oncology still has to prove its H2 momentum is durable. The 2026 guide feels achievable if FRUZAQLA® keeps compounding and the China team maintains its second-half pace.

In short, this is a transition year: from heavy investment to a more selective R&D push behind ATTC, while sweating the commercial assets harder. If partnerships land and SAFFRON reads out well, the equity story strengthens. If China stalls or ATTC data disappoints, the wide guidance could come under pressure. For now, the cash cushion buys time to execute.